KABRA DRUGS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.91 INR | 0.00% |
|
0.00% | +46.75% |
Valuation
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 13.82 | 2.458 | 13.78 | 19.79 | 19.97 | 24.44 |
| Enterprise Value (EV) 1 | 19.71 | 9.035 | 20.2 | 28.7 | 30.21 | 38.23 |
| P/E ratio | -0.59 x | -1.49 x | -23.1 x | -11 x | -10.8 x | -7.23 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 0.77 x | - | - | - | - | - |
| EV / Revenue | 1.09 x | - | - | - | - | - |
| EV / EBITDA | -1.91 x | -6.64 x | -41.5 x | -19.4 x | -17.3 x | -11.4 x |
| EV / FCF | 11.5 x | -14.1 x | -127 x | -15.9 x | -47.5 x | -16.5 x |
| FCF Yield | 8.66% | -7.08% | -0.79% | -6.3% | -2.1% | -6.06% |
| Price to Book | 7.03 x | 7.71 x | -49.7 x | -9.53 x | -5.08 x | -3.34 x |
| Nbr of stocks (in thousands) | 4,389 | 4,389 | 4,389 | 4,389 | 4,389 | 4,389 |
| Reference price 2 | 3.150 | 0.5600 | 3.140 | 4.510 | 4.550 | 5.570 |
| Announcement Date | 8/23/18 | 9/28/19 | 9/9/20 | 9/8/21 | 9/29/22 | 10/25/23 |
1INR in Million2INR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 18.02 | - | - | - | - | - |
| EBITDA 1 | -10.31 | -1.36 | -0.4868 | -1.476 | -1.742 | -3.343 |
| EBIT 1 | -11.68 | -1.673 | -0.7994 | -1.789 | -1.842 | -3.443 |
| Operating Margin | -64.81% | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -23.57 | -1.647 | -0.5959 | -1.8 | -1.854 | -3.379 |
| Net income 1 | -23.57 | -1.647 | -0.5959 | -1.8 | -1.854 | -3.379 |
| Net margin | -130.74% | - | - | - | - | - |
| EPS 2 | -5.370 | -0.3754 | -0.1358 | -0.4102 | -0.4224 | -0.7700 |
| Free Cash Flow 1 | 1.708 | -0.6396 | -0.1587 | -1.809 | -0.6355 | -2.317 |
| FCF margin | 9.47% | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 8/23/18 | 9/28/19 | 9/9/20 | 9/8/21 | 9/29/22 | 10/25/23 |
1INR in Million2INR
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 5.89 | 6.58 | 6.42 | 8.91 | 10.2 | 13.8 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | -0.5713 x | -4.835 x | -13.18 x | -6.035 x | -5.88 x | -4.125 x |
| Free Cash Flow 1 | 1.71 | -0.64 | -0.16 | -1.81 | -0.64 | -2.32 |
| ROE (net income / shareholders' equity) | -171% | -144% | -2,869% | 153% | 61.7% | 60.1% |
| ROA (Net income/ Total Assets) | -18.1% | -6.58% | -3.45% | -7.94% | -10.8% | -30% |
| Assets 1 | 130.5 | 25.05 | 17.28 | 22.69 | 17.17 | 11.25 |
| Book Value Per Share 2 | 0.4500 | 0.0700 | -0.0600 | -0.4700 | -0.9000 | -1.670 |
| Cash Flow per Share 2 | 0.2600 | 0.0200 | 0.0200 | 0.0200 | 0 | 0.0100 |
| Capex 1 | 0.13 | - | - | - | - | - |
| Capex / Sales | 0.74% | - | - | - | - | - |
| Announcement Date | 8/23/18 | 9/28/19 | 9/9/20 | 9/8/21 | 9/29/22 | 10/25/23 |
1INR in Million2INR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
- Stock Market
- Equities
- 524322 Stock
- Financials Kabra Drugs Limited
